Format

Send to

Choose Destination
Lancet Oncol. 2020 Feb;21(2):e74-e82. doi: 10.1016/S1470-2045(20)30034-6.

MRI-guided adaptive radiotherapy for liver tumours: visualising the future.

Author information

1
Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.
2
Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
3
Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: bassetti@humonc.wisc.edu.

Abstract

MRI-guided radiotherapy is a novel and rapidly evolving technology that might enhance the risk-benefit ratio. Through direct visualisation of the tumour and the nearby healthy tissues, the radiation oncologist can deliver highly accurate treatment even to mobile targets. Each individual treatment can be customised to changing anatomy, potentially reducing the risk of radiation-related toxicities while simultaneously increasing the dose delivered to the tumour. MRI-guided radiotherapy offers a new tool for the radiation oncologist, and creates an opportunity to achieve durable local control of liver tumours that might not otherwise be possible. Future work will allow us to expand the population eligible for curative-intent radiotherapy, optimise and customise radiation doses to specific tumours, and hopefully create opportunities for improving outcomes through machine learning and radiomics-based approaches. This Review outlines the current and future applications for MRI-guided radiotherapy with respect to metastatic and primary liver cancers.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center